Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.44 |
| ▸ | MLYCD | O95822 | 2/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.37 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7799119 | 0.91 | MEN1 (0.43) | ROCK2ROCK1CFTR | |
| SCHEMBL7799131 | 0.87 | PDK2 (0.36) | ADORA2A | |
| SCHEMBL7799172 | 0.85 | PDK2 (0.33) | — | |
| SCHEMBL7803166 | 0.83 | LMNA (0.42) | CFTR | |
| SCHEMBL7802386 | 0.83 | KMT2A (0.40) | ROCK2ROCK1 | |
| SCHEMBL7799355 | 0.82 | HPGD (0.34) | CFTR | |
| SCHEMBL8437417 | 0.81 | HCAR3 (0.33) | MLYCDCFTR | |
| SCHEMBL7793529 | 0.79 | RIPK1 (0.37) | — | |
| SCHEMBL7801055 | 0.79 | HPGD (0.39) | CFTR | |
| SCHEMBL6981270 | 0.79 | PSMD14 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027351-A1 | PHENANTHROLINE DERIVATIVES | FIBROGEN, INC. (US) | 2000-08-16 | — | — | EP | claimed |
| WO-1999021860-B1 | PHENANTHROLINE DERIVATIVES | FIBROGEN INC (US) | 1999-08-05 | — | — | WO | claimed |
| WO-1999021860-A1 | PHENANTHROLINE DERIVATIVES | FIBROGEN, INC. (US) | 1999-05-06 | — | — | WO | claimed |
| US-20010001101-A1 | Phenanthroline derivatives | ZENECA LIMITED | 2001-05-10 | — | — | US | disclosed |
| EP-1027351-A1 | PHENANTHROLINE DERIVATIVES | FIBROGEN, INC. (US) | 2000-08-16 | — | — | EP | disclosed |
| US-5916898-A | ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 1999-06-29 | — | — | US | disclosed |
| WO-1999021860-A1 | PHENANTHROLINE DERIVATIVES | FIBROGEN, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010001101-A1 | Phenanthroline derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 | ROCK2 2326/4885ROCK1 941/4885MLYCD 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.